←Back to Expert Scholars
Translational Medicine / 转化医学ROS1 Fusion Resistance Mechanisms
Sai-Hong Ignatius Ou
MD, PhD
🏢University of California Irvine🌐USA
Professor of Medicine
68
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Sai-Hong Ignatius Ou is one of the original investigators of crizotinib activity in ROS1-rearranged NSCLC. He has documented resistance patterns to first-generation ROS1 inhibitors and contributed to next-generation agent development. His clinical research program addresses rare molecular subtypes of lung cancer.
Share:
🧪Research Fields 研究领域
ROS1 fusions
Crizotinib
Entrectinib
Rare molecular subtypes
NSCLC treatment
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Sai-Hong Ignatius Ou 的研究动态
Follow Sai-Hong Ignatius Ou's research updates
留下邮箱，当我们发布与 Sai-Hong Ignatius Ou（University of California Irvine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment